Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Similar articles for PubMed (Select 24468255)

1.

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.

Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H.

Ann Allergy Asthma Immunol. 2014 Feb;112(2):146-153.e2. doi: 10.1016/j.anai.2013.11.018. Epub 2013 Dec 21.

PMID:
24468255
2.

Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.

Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G.

JAMA Intern Med. 2015 Jun 29. doi: 10.1001/jamainternmed.2015.2840. [Epub ahead of print]

PMID:
26120825
3.

Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score.

Didier A, Malling HJ, Worm M, Horak F, Sussman GL.

Clin Transl Allergy. 2015 May 22;5:12. doi: 10.1186/s13601-015-0057-8. eCollection 2015.

4.

Allergy immunotherapy prescribing trends for grass pollen-induced allergic rhinitis in Germany: a retrospective cohort analysis.

McDonell AL, Wahn U, Demuth D, Richards C, Hawes C, Andreasen JN, Allen-Ramey F.

Allergy Asthma Clin Immunol. 2015 Jun 10;11(1):19. doi: 10.1186/s13223-015-0085-x. eCollection 2015.

5.

A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines.

Sola J, Sánchez V, Landeta A, Madariaga B, Martínez A, Álvarez-Cuesta E.

Immunotherapy. 2015;7(4):343-52. doi: 10.2217/imt.15.8.

PMID:
25917626
6.

A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy.

Ciprandi G.

J Asthma Allergy. 2015 Mar 6;8:25-7. doi: 10.2147/JAA.S82077. eCollection 2015. No abstract available.

7.

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis.

Kim H, Waserman S, Hébert J, Blaiss M, Nelson H, Creticos P, Kaur A, Maloney J, Li Z, Nolte H.

Allergy Asthma Clin Immunol. 2014 Nov 10;10(1):55. doi: 10.1186/1710-1492-10-55. eCollection 2014.

8.

Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review.

Didier A, Bons B.

Expert Opin Drug Saf. 2015 May;14(5):777-88. doi: 10.1517/14740338.2015.1017468. Epub 2015 Mar 3.

PMID:
25732009
9.

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children.

Hébert J, Blaiss M, Waserman S, Kim H, Creticos P, Maloney J, Kaur A, Li Z, Nelson H, Nolte H.

Allergy Asthma Clin Immunol. 2014 Oct 30;10(1):53. doi: 10.1186/1710-1492-10-53. eCollection 2014.

10.

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

Nolte H, Maloney J, Nelson HS, Bernstein DI, Lu S, Li Z, Kaur A, Zieglmayer P, Zieglmayer R, Lemell P, Horak F.

J Allergy Clin Immunol. 2015 Jun;135(6):1494-1501.e6. doi: 10.1016/j.jaci.2014.12.1911. Epub 2015 Jan 27.

PMID:
25636947
11.

SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.

Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, Ljørring C.

Ann Allergy Asthma Immunol. 2015 Feb;114(2):134-40. doi: 10.1016/j.anai.2014.11.015.

12.

Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.

Kruse K, Gerwin E, Eichel A, Shah-Hosseini K, Mösges R.

J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):381-6. doi: 10.1016/j.jaip.2014.10.015. Epub 2015 Jan 22.

PMID:
25609338
13.

Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy.

Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA.

J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):256-266.e3. doi: 10.1016/j.jaip.2014.09.018. Epub 2014 Nov 20.

PMID:
25609326
14.

Comment on 'Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation'.

Hsiao KC, Smart J.

Pediatr Allergy Immunol. 2015 Feb;26(1):92. doi: 10.1111/pai.12329. No abstract available.

PMID:
25557000
15.
16.

Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma.

Maloney J, Durham S, Skoner D, Dahl R, Bufe A, Bernstein D, Murphy K, Waserman S, Berman G, White M, Kaur A, Nolte H.

Allergy. 2015 Mar;70(3):302-9. doi: 10.1111/all.12560. Epub 2015 Jan 14.

PMID:
25495666
17.

Grass pollen immunotherapy for treatment of allergic rhinitis.

Slovick A, Durham SR, Till SJ.

BMJ. 2014 Nov 17;349:g6586. doi: 10.1136/bmj.g6586. No abstract available.

PMID:
25403477
18.

An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents.

Eberle P, Brueck H, Gall R, Hadler M, Sieber J, Karagiannis E.

Pediatr Allergy Immunol. 2014 Dec;25(8):760-6. doi: 10.1111/pai.12298. Epub 2014 Dec 29.

PMID:
25378225
19.

Efficacy and Safety of Grass Sublingual Immunotherapy Tablet, MK-7243: A Large Randomized Controlled Trial.

Winterroth LC, Willams PV.

Pediatrics. 2014 Nov;134 Suppl 3:S161-2. doi: 10.1542/peds.2014-1817XX. No abstract available.

PMID:
25363956
20.

300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.

Serrano E, Wahn HU, Didier A, Bachert C.

Am J Rhinol Allergy. 2014 Nov-Dec;28(6):471-6. doi: 10.2500/ajra.2014.28.4112. Epub 2014 Oct 20.

PMID:
25335122
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk